Efficacy and Safety of Dry Powder Antibiotics

The use of inhaled antibiotics was initially almost exclusively confined to patients with cystic fibrosis (CF). However, it has been extended in recent decades to patients with non-CF bronchiectasis or chronic obstructive pulmonary disease who present with chronic bronchial infection by potentially...

Descripción completa

Detalles Bibliográficos
Autores: de la Rosa Carrillo, David|||0000-0003-0753-1771, Suarez-Cuartin, Guillermo|||0000-0003-2320-6047, Sibila, Oriol|||0000-0002-4833-6713, Golpe, Rafael|||0000-0002-3759-5322, Girón, Rosa|||0000-0001-7094-0848, Martínez García, Miguel Ángel|||0000-0002-7321-1891
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:301716
Acceso en línea:https://ddd.uab.cat/record/301716
https://dx.doi.org/urn:doi:10.3390/jcm12103577
Access Level:acceso abierto
Palabra clave:Antibiotics
Bronchiectasis
Chronic bronchial infection
Cystic fibrosis
Dry powder antibiotics
Inhalation drug
Pseudomonas aeruginosa
id ES_daadeb3d3e346a89ef5bdbb9897678e5
oai_identifier_str oai:ddd.uab.cat:301716
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy and Safety of Dry Powder AntibioticsA Narrative Reviewde la Rosa Carrillo, David|||0000-0003-0753-1771Suarez-Cuartin, Guillermo|||0000-0003-2320-6047Sibila, Oriol|||0000-0002-4833-6713Golpe, Rafael|||0000-0002-3759-5322Girón, Rosa|||0000-0001-7094-0848Martínez García, Miguel Ángel|||0000-0002-7321-1891AntibioticsBronchiectasisChronic bronchial infectionCystic fibrosisDry powder antibioticsInhalation drugPseudomonas aeruginosaThe use of inhaled antibiotics was initially almost exclusively confined to patients with cystic fibrosis (CF). However, it has been extended in recent decades to patients with non-CF bronchiectasis or chronic obstructive pulmonary disease who present with chronic bronchial infection by potentially pathogenic microorganisms. Inhaled antibiotics reach high concentrations in the area of infection, which enhances their effect and enables their long-term administration to defeat the most resistant infections, while minimizing possible adverse effects. New formulations of inhaled dry powder antibiotics have been developed, providing, among other advantages, faster preparation and administration of the drug, as well as avoiding the requirement to clean nebulization equipment. In this review, we analyze the advantages and disadvantages of the different types of devices that allow the inhalation of antibiotics, especially dry powder inhalers. We describe their general characteristics, the different inhalers on the market and the proper way to use them. We analyze the factors that influence the way in which the dry powder drug reaches the lower airways, as well as aspects of microbiological effectiveness and risks of resistance development. We review the scientific evidence on the use of colistin and tobramycin with this type of device, both in patients with CF and with non-CF bronchiectasis. Finally, we discuss the literature on the development of new dry powder antibiotics.Universitat Autònoma de Barcelona 22023-01-0120232023-01-01Article de revisióhttp://purl.org/coar/resource_type/c_dcae04bcVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/301716https://dx.doi.org/urn:doi:10.3390/jcm12103577reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3017162026-06-06T12:50:31Z
dc.title.none.fl_str_mv Efficacy and Safety of Dry Powder Antibiotics
A Narrative Review
title Efficacy and Safety of Dry Powder Antibiotics
spellingShingle Efficacy and Safety of Dry Powder Antibiotics
de la Rosa Carrillo, David|||0000-0003-0753-1771
Antibiotics
Bronchiectasis
Chronic bronchial infection
Cystic fibrosis
Dry powder antibiotics
Inhalation drug
Pseudomonas aeruginosa
title_short Efficacy and Safety of Dry Powder Antibiotics
title_full Efficacy and Safety of Dry Powder Antibiotics
title_fullStr Efficacy and Safety of Dry Powder Antibiotics
title_full_unstemmed Efficacy and Safety of Dry Powder Antibiotics
title_sort Efficacy and Safety of Dry Powder Antibiotics
dc.creator.none.fl_str_mv de la Rosa Carrillo, David|||0000-0003-0753-1771
Suarez-Cuartin, Guillermo|||0000-0003-2320-6047
Sibila, Oriol|||0000-0002-4833-6713
Golpe, Rafael|||0000-0002-3759-5322
Girón, Rosa|||0000-0001-7094-0848
Martínez García, Miguel Ángel|||0000-0002-7321-1891
author de la Rosa Carrillo, David|||0000-0003-0753-1771
author_facet de la Rosa Carrillo, David|||0000-0003-0753-1771
Suarez-Cuartin, Guillermo|||0000-0003-2320-6047
Sibila, Oriol|||0000-0002-4833-6713
Golpe, Rafael|||0000-0002-3759-5322
Girón, Rosa|||0000-0001-7094-0848
Martínez García, Miguel Ángel|||0000-0002-7321-1891
author_role author
author2 Suarez-Cuartin, Guillermo|||0000-0003-2320-6047
Sibila, Oriol|||0000-0002-4833-6713
Golpe, Rafael|||0000-0002-3759-5322
Girón, Rosa|||0000-0001-7094-0848
Martínez García, Miguel Ángel|||0000-0002-7321-1891
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Antibiotics
Bronchiectasis
Chronic bronchial infection
Cystic fibrosis
Dry powder antibiotics
Inhalation drug
Pseudomonas aeruginosa
topic Antibiotics
Bronchiectasis
Chronic bronchial infection
Cystic fibrosis
Dry powder antibiotics
Inhalation drug
Pseudomonas aeruginosa
description The use of inhaled antibiotics was initially almost exclusively confined to patients with cystic fibrosis (CF). However, it has been extended in recent decades to patients with non-CF bronchiectasis or chronic obstructive pulmonary disease who present with chronic bronchial infection by potentially pathogenic microorganisms. Inhaled antibiotics reach high concentrations in the area of infection, which enhances their effect and enables their long-term administration to defeat the most resistant infections, while minimizing possible adverse effects. New formulations of inhaled dry powder antibiotics have been developed, providing, among other advantages, faster preparation and administration of the drug, as well as avoiding the requirement to clean nebulization equipment. In this review, we analyze the advantages and disadvantages of the different types of devices that allow the inhalation of antibiotics, especially dry powder inhalers. We describe their general characteristics, the different inhalers on the market and the proper way to use them. We analyze the factors that influence the way in which the dry powder drug reaches the lower airways, as well as aspects of microbiological effectiveness and risks of resistance development. We review the scientific evidence on the use of colistin and tobramycin with this type of device, both in patients with CF and with non-CF bronchiectasis. Finally, we discuss the literature on the development of new dry powder antibiotics.
publishDate 2023
dc.date.none.fl_str_mv 2
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv Article de revisió
http://purl.org/coar/resource_type/c_dcae04bc
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/301716
https://dx.doi.org/urn:doi:10.3390/jcm12103577
url https://ddd.uab.cat/record/301716
https://dx.doi.org/urn:doi:10.3390/jcm12103577
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421602306785280
score 15,812455

Similares en LA Referencia